Biogen (NASDAQ:BIIB) Reaches New 12-Month High After Analyst Upgrade

Biogen Inc. (NASDAQ:BIIB) reached a new 52-week high during mid-day trading on Monday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. JPMorgan Chase & Co. now has a $300.00 price target on the stock, up from their previous price target of $210.00. Biogen traded as high as $233.05 and last traded at $235.0730, with a volume of 20,833 shares traded. The stock had previously closed at $225.71.

BIIB has been the subject of several other reports. Barclays upped their target price on Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 29th. Guggenheim raised their target price on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Seaport Research Partners upgraded Biogen to an “outperform” rating in a research note on Monday. Zacks Research raised Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Wedbush boosted their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $236.04.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: J.P. Morgan said Biogen has an increasingly compelling catalyst path, highlighting potential 2027 data readouts for felzartamab in antibody-mediated rejection and litifilimab in cutaneous lupus erythematosus (CLE). The new target implies substantial upside from recent trading levels. JPMorgan Upgrades Biogen to Overweight From Neutral
• Positive Sentiment: Biogen’s 52-week Phase 2 AMETHYST data for litifilimab showed sustained improvements in skin disease activity among difficult-to-treat CLE patients, with a generally well-tolerated safety profile. The program also has FDA Breakthrough Therapy Designation, supporting its potential as a first-in-class, once-monthly treatment. What Biogen’s 52-Week Litifilimab CLE Data Means
• Positive Sentiment: Recent pipeline updates have strengthened the view that Biogen’s investment case is becoming less dependent on its Alzheimer’s franchise. The stock has also delivered strong recent performance, while one analysis characterized the shares as modestly undervalued despite that run. Biogen Could Be Undervalued After 52-Week Lupus Data
• Neutral Sentiment: Biogen is scheduled to report third-quarter 2026 results on October 28. The release could provide a near-term confirmation of operating trends and updated expectations ahead of the larger 2027 clinical catalysts.
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: several large investors, including FMR and JPMorgan, increased holdings, while VanEck, Point72 and T. Rowe Price reduced positions. This suggests improving interest but not uniform conviction.
• Negative Sentiment: Reported insider activity was limited but consisted of two sales and no purchases over the past six months. While not a major catalyst compared with the analyst upgrade, it provides a modest counterpoint to the bullish sentiment.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. lifted its stake in shares of Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 56 shares during the period. Meeder Advisory Services Inc. boosted its position in shares of Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares in the last quarter. Kera Capital Partners Inc. grew its stake in Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 58 shares during the period. Parallel Advisors LLC grew its stake in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares during the period. Finally, Rehmann Capital Advisory Group grew its stake in Biogen by 6.1% during the second quarter. Rehmann Capital Advisory Group now owns 1,236 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 71 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

The firm has a market capitalization of $33.90 billion, a P/E ratio of 40.60, a P/E/G ratio of 2.49 and a beta of 0.09. The stock has a fifty day simple moving average of $217.96 and a two-hundred day simple moving average of $202.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company’s revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts predict that Biogen Inc. will post 12.41 EPS for the current year.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.